HRP20161389T1 - Derivati pantotenata namijenjeni liječenju neuroloških poremećaja - Google Patents
Derivati pantotenata namijenjeni liječenju neuroloških poremećaja Download PDFInfo
- Publication number
- HRP20161389T1 HRP20161389T1 HRP20161389TT HRP20161389T HRP20161389T1 HR P20161389 T1 HRP20161389 T1 HR P20161389T1 HR P20161389T T HRP20161389T T HR P20161389TT HR P20161389 T HRP20161389 T HR P20161389T HR P20161389 T1 HRP20161389 T1 HR P20161389T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- intended
- compound according
- subject
- treatment
- Prior art date
Links
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- -1 1H-indol-3yl-methyl Chemical group 0.000 claims 1
- 108010021592 Pantothenate kinase Proteins 0.000 claims 1
- 102100024122 Pantothenate kinase 1 Human genes 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Claims (14)
1. Spoj s formulom:
[image]
,
ili njegova farmaceutski prihvatljiva sol, naznačen time što se bira iz skupine koju čine:
[image]
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što su R, R′ i R″ metili.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R metil, R′ je etil, a R″ je benzil.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R metil, a R′ i R″ su metilciklopropili.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R 1H-indol-3il-metil, R′ je benzil, a R″ je etil.
6. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, kao i farmaceutski prihvatljivu pomoćnu tvar.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je farmaceutski pripravak oblik jedinice doziranja.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi kao medikament za liječenje neurodegeneracije kod subjekta povezane s pantotenat-kinazom.
9. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što subjekt boluje od neurodegeneracije uz nakupljanje željeza u mozgu.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi kao medikament za liječenje subjekta u čijim živčanim stanicama dolazi do prekomjernog nakupljanja željeza.
11. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 8-10, naznačen time što je subjekt dijete.
12. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je dijete staro 10 do 15 godina.
13. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 8-10, naznačen time što je subjekt odrasla osoba.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, namijenjen upotrebi kao medikament za liječenje stanica ili tkiva uključenih u patologiju, naznačenu time što živčano tkivo kod subjekta funkcionira abnormalno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639602P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038458 WO2013163576A1 (en) | 2012-04-27 | 2013-04-26 | Pantothenate derivatives for the treatment of neurologic disorders |
| EP13722201.4A EP2841438B1 (en) | 2012-04-27 | 2013-04-26 | Pantothenate derivatives for the treatment of neurologic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161389T1 true HRP20161389T1 (hr) | 2016-12-02 |
Family
ID=48428654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161389TT HRP20161389T1 (hr) | 2012-04-27 | 2016-10-25 | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja |
| HRP20190038TT HRP20190038T1 (hr) | 2012-04-27 | 2019-01-04 | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190038TT HRP20190038T1 (hr) | 2012-04-27 | 2019-01-04 | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8673883B2 (hr) |
| EP (3) | EP3112372B1 (hr) |
| JP (3) | JP6254151B2 (hr) |
| KR (1) | KR20150035550A (hr) |
| CN (2) | CN106977544B (hr) |
| AU (3) | AU2013251345B2 (hr) |
| BR (1) | BR112014026817A2 (hr) |
| CA (1) | CA2879314A1 (hr) |
| CY (2) | CY1118198T1 (hr) |
| DK (2) | DK3112372T3 (hr) |
| ES (2) | ES2708813T3 (hr) |
| HK (1) | HK1207863A1 (hr) |
| HR (2) | HRP20161389T1 (hr) |
| HU (2) | HUE042199T2 (hr) |
| IN (1) | IN2014DN09584A (hr) |
| LT (2) | LT2841438T (hr) |
| MX (1) | MX360149B (hr) |
| PL (2) | PL2841438T3 (hr) |
| PT (2) | PT3112372T (hr) |
| RS (2) | RS55319B1 (hr) |
| RU (2) | RU2653497C2 (hr) |
| SI (2) | SI3112372T1 (hr) |
| SM (1) | SMT201600395B (hr) |
| TR (1) | TR201819263T4 (hr) |
| WO (1) | WO2013163576A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2708813T3 (es) * | 2012-04-27 | 2019-04-11 | Retrophin Inc | Derivados del pantotenato para el tratamiento de trastornos neurológicos |
| EP3060570B1 (en) | 2013-10-25 | 2018-09-19 | Retrophin, Inc. | Pantothenate derivatives for the treatment of neurological disorders |
| EP2868662A1 (en) | 2013-11-04 | 2015-05-06 | Acies Bio d.o.o. | Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds |
| MX2018006636A (es) * | 2015-12-08 | 2018-08-15 | Retrophin Inc | Fosfatos ciclicos y fosforoamidatos ciclicos para el tratamiento de trastornos neurologicos. |
| US20200121604A1 (en) * | 2017-02-07 | 2020-04-23 | Retrophin, Inc. | Solid fosmetpantotenate formulations |
| US11746087B1 (en) | 2022-03-18 | 2023-09-05 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2676976A (en) | 1950-12-04 | 1954-04-27 | Nat Res Dev | Synthesis of pantothenic acid-4' phosphate |
| US2870188A (en) | 1955-10-03 | 1959-01-20 | Hoffmann La Roche | Process for the manufacture of pantothenic acid 4'-phosphate and its salts |
| RU2002110463A (ru) * | 1999-09-21 | 2004-02-27 | Басф Акциенгезелльшафт (De) | Способ и микроорганизмы для получения пантосоединений |
| AU2002326412A1 (en) | 2001-07-20 | 2003-03-03 | Oregon Health And Science University | Novel human nucleic acids encoding a pantothenate kinase and methods of use |
| CN100455669C (zh) * | 2002-07-03 | 2009-01-28 | 巴斯福股份公司 | 用于提高泛酸产量的微生物和方法 |
| CN101287472B (zh) | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| ES2708813T3 (es) * | 2012-04-27 | 2019-04-11 | Retrophin Inc | Derivados del pantotenato para el tratamiento de trastornos neurológicos |
-
2013
- 2013-04-26 ES ES16001739T patent/ES2708813T3/es active Active
- 2013-04-26 US US13/871,691 patent/US8673883B2/en not_active Expired - Fee Related
- 2013-04-26 AU AU2013251345A patent/AU2013251345B2/en not_active Ceased
- 2013-04-26 RS RS20160939A patent/RS55319B1/sr unknown
- 2013-04-26 SI SI201331263T patent/SI3112372T1/sl unknown
- 2013-04-26 CN CN201611221824.7A patent/CN106977544B/zh not_active Expired - Fee Related
- 2013-04-26 IN IN9584DEN2014 patent/IN2014DN09584A/en unknown
- 2013-04-26 MX MX2014013048A patent/MX360149B/es active IP Right Grant
- 2013-04-26 JP JP2015509192A patent/JP6254151B2/ja not_active Expired - Fee Related
- 2013-04-26 ES ES13722201.4T patent/ES2600179T3/es active Active
- 2013-04-26 HU HUE16001739A patent/HUE042199T2/hu unknown
- 2013-04-26 LT LTEP13722201.4T patent/LT2841438T/lt unknown
- 2013-04-26 CA CA2879314A patent/CA2879314A1/en not_active Abandoned
- 2013-04-26 LT LTEP16001739.8T patent/LT3112372T/lt unknown
- 2013-04-26 EP EP16001739.8A patent/EP3112372B1/en active Active
- 2013-04-26 EP EP13722201.4A patent/EP2841438B1/en active Active
- 2013-04-26 EP EP18201414.2A patent/EP3489248A1/en not_active Withdrawn
- 2013-04-26 PL PL13722201T patent/PL2841438T3/pl unknown
- 2013-04-26 WO PCT/US2013/038458 patent/WO2013163576A1/en active Application Filing
- 2013-04-26 SI SI201330307A patent/SI2841438T1/sl unknown
- 2013-04-26 PT PT16001739T patent/PT3112372T/pt unknown
- 2013-04-26 CN CN201380033271.0A patent/CN104520307B/zh not_active Expired - Fee Related
- 2013-04-26 RU RU2014147739A patent/RU2653497C2/ru not_active IP Right Cessation
- 2013-04-26 KR KR20147033141A patent/KR20150035550A/ko active IP Right Grant
- 2013-04-26 HU HUE13722201A patent/HUE029474T2/en unknown
- 2013-04-26 DK DK16001739.8T patent/DK3112372T3/en active
- 2013-04-26 PT PT137222014T patent/PT2841438T/pt unknown
- 2013-04-26 DK DK13722201.4T patent/DK2841438T3/en active
- 2013-04-26 PL PL16001739T patent/PL3112372T3/pl unknown
- 2013-04-26 RS RS20190049A patent/RS58336B1/sr unknown
- 2013-04-26 BR BR112014026817A patent/BR112014026817A2/pt not_active Application Discontinuation
- 2013-04-26 RU RU2018112720A patent/RU2018112720A/ru not_active Application Discontinuation
- 2013-04-26 TR TR2018/19263T patent/TR201819263T4/tr unknown
-
2014
- 2014-01-16 US US14/157,173 patent/US9181286B2/en not_active Expired - Fee Related
-
2015
- 2015-09-01 HK HK15108533.0A patent/HK1207863A1/xx not_active IP Right Cessation
- 2015-09-30 US US14/871,450 patent/US9629862B2/en not_active Expired - Fee Related
-
2016
- 2016-10-25 HR HRP20161389TT patent/HRP20161389T1/hr unknown
- 2016-11-03 SM SM201600395T patent/SMT201600395B/it unknown
- 2016-11-04 CY CY20161101130T patent/CY1118198T1/el unknown
-
2017
- 2017-03-22 JP JP2017055792A patent/JP6560284B2/ja not_active Expired - Fee Related
- 2017-10-04 AU AU2017239508A patent/AU2017239508C1/en not_active Ceased
-
2019
- 2019-01-04 HR HRP20190038TT patent/HRP20190038T1/hr unknown
- 2019-02-05 CY CY20191100156T patent/CY1121238T1/el unknown
- 2019-07-18 JP JP2019132651A patent/JP2019206553A/ja active Pending
- 2019-08-20 AU AU2019219733A patent/AU2019219733A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
| HRP20171512T1 (hr) | Derivati betulina | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| EA201791239A1 (ru) | ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| WO2015042078A8 (en) | Substituted aminopyrimidine compounds and methods of use | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
| EP2958486A4 (en) | DEVICE FOR ENABLING PATIENT SICKNESS TESTS AND TREATMENT INDIVIDUAL MANAGEMENT, AND SYSTEM WITH THE DEVICE FOR MANAGING HEALTH CARE FOR A PATIENT | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| IL233557A0 (en) | Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failed | |
| MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
| WO2013166037A9 (en) | Non-retinoid antagonists for treatment of eye disorders | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| EA201290694A1 (ru) | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы | |
| SG11201408323RA (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a |